Seres Therapeutics, Inc. (NASDAQ:MCRB)
| Market Cap | $12.64M-92.7% |
| Revenue (ttm) | $2.13M+505.4% |
| Net Income | -$46.95M-970.5% |
| EPS | -$4.95-911.5% |
| Shares Out | 10.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 56,761 |
| Open | $1.36 |
| Previous Close | $1.33 |
| Day's Range | $1.22 - $1.37 |
| 52-Week Range | $1.20 - $18.86 |
| Beta | 0.21 |
| Analysts | Buy |
| Price Target | $12.00(+867.74%) |
| Earnings Date | Mar 11, 2027 |
About MCRB
Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile infection (CDI). The company's pipeline further encompasses SER-155, a synthetically cultured bacterial formulation currently undergoing Phase Ib evaluation. This candidate aims to mitigate the risk of gastrointestinal and bloodstream infections, alongside graft-versus-host disease, in vulnerable patients undergoing allogeneic hematopoietic stem cell or solid organ transplantation. Additionally, Seres Therapeutics is advancing SER-287 and SER-301, both in Phase Ib for ulcerative colitis, as well as SER-401, which targets metastatic melanoma, and SER-262, also directed at Clostridioides difficile infection. Seres maintains strategic alliances through licensing and collaboration agreements with entities such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center. Established in 2010, the company previously operated as Seres Health, Inc. before adopting its current name in May 2015, and it maintains its principal offices in Cambridge, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 11, 2027Earnings report
$MCRB stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in MCRB holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MCRB's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MCRB Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New MCRB patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MCRB from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in MCRB
| VTIVanguard Morningstar Total Stock Market ETF | $287.57K |
| VXFVanguard Extended Market ETF | $134.25K |
| IWCiShares Micro-Cap ETF | $30.66K |
| EESWisdomTree U.S. SmallCap Fund | $23.72K |
| PRFZInvesco RAFI US 1500 Small-Mid ETF | $16.67K |
| BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | $10.00K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from MCRB’s recent data — informational, not investment advice
